Molecular Pathology of Colon and Small Bowel Cancers: Sporadic Type

  • Asif RashidEmail author
Part of the Molecular Pathology Library book series (MPLB, volume 7)


Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third most common cause of cancer death in men and women in the USA and accounts for 9 % of all new cancer cases and of all cancer deaths. In contrast, the incidence of small bowel cancer is low and accounts for 0.4 % of all new cases and 0.2 % of all cancer deaths. It is currently believed that most sporadic colorectal cancers arise from preexisting precursor lesions, including adenoma, dysplasia and recently serrated polyps, but a small percentage of colorectal cancers can arise de novo without identifiable precursor lesions. The majority of colorectal cancers develop through an “adenoma–carcinoma sequence” beginning from transformation of normal colorectal epithelium to an adenomatous intermediate and then to adenocarcinoma. The molecular pathogenesis of colorectal cancer including genetic and epigenetic alterations has been extensively studied in the past two decades and is among one the best understood among human neoplasms.


Colorectal Cancer Adenomatous Polyposis Coli Aberrant Crypt Focus Adenomatous Polyposis Coli Gene Serrate Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Morson B. President’s address: the polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974;67:451–457.PubMedGoogle Scholar
  3. 3.
    Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.PubMedCrossRefGoogle Scholar
  4. 4.
    Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 1999;59:2307–2312.PubMedGoogle Scholar
  5. 5.
    Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000;97:710–715.PubMedCrossRefGoogle Scholar
  6. 6.
    Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG Island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681–8686.PubMedCrossRefGoogle Scholar
  7. 7.
    Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–561.PubMedCrossRefGoogle Scholar
  8. 8.
    Thibodeau SN, Berg G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816–819.PubMedCrossRefGoogle Scholar
  9. 9.
    Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal cancer syndrome. Cancer Res. 1993;53:5853–5855.PubMedGoogle Scholar
  10. 10.
    Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–1113.PubMedCrossRefGoogle Scholar
  11. 11.
    Leary R, Lin J, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA. 2008;105:16226–16229.CrossRefGoogle Scholar
  12. 12.
    Powell S, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumoriogenesis. Nature. 1992;359:235–237.PubMedCrossRefGoogle Scholar
  13. 13.
    Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170.PubMedCrossRefGoogle Scholar
  14. 14.
    Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104:1044–1048.PubMedGoogle Scholar
  15. 15.
    Moerkerk P, Arends JW, van Driel M, et al. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res. 1994;54:3376–3378.PubMedGoogle Scholar
  16. 16.
    Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270–1275.PubMedCrossRefGoogle Scholar
  17. 17.
    Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse tumor types. Nature. 1989;342:705–708.PubMedCrossRefGoogle Scholar
  18. 18.
    Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late event in colorectal tumorigenesis. Cancer Res. 1990;50:7717–7722.PubMedGoogle Scholar
  19. 19.
    Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247:49–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet. 1996;13:343–346.PubMedCrossRefGoogle Scholar
  21. 21.
    Bacolod MD, Barany F. Gene dysregulation driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diag. 2010;12:552–561.CrossRefGoogle Scholar
  22. 22.
    Cottrell S, Bicknell D, Kaklamanis L, et al. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet. 1992;340:626–630.PubMedCrossRefGoogle Scholar
  23. 23.
    Miyaki M, Konishi M, Kikuchi-Yanoshita R, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res. 1994;54:3011–3020.PubMedGoogle Scholar
  24. 24.
    Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992;1:229–233.PubMedCrossRefGoogle Scholar
  25. 25.
    Otori K, Konishi M, Sugiyama K, et al. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer. 1998;83:896–900.PubMedCrossRefGoogle Scholar
  26. 26.
    Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60:4366–4371.PubMedGoogle Scholar
  27. 27.
    Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3b to the APC-b-catenin complex and regulation of complex assembly. Science. 1996;272:1023–1026.PubMedCrossRefGoogle Scholar
  28. 28.
    Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T-cell-factor/lymphoid-enhancer-factor signaling in human ­colorectal carcinomas. Proc Natl Acad Sci USA. 1999;96: 1603–1608.PubMedCrossRefGoogle Scholar
  29. 29.
    Sparks A, Morin P, Vogelstein B, et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130–1134.PubMedGoogle Scholar
  30. 30.
    Shimizu Y, Ikeda S, Fujimori M, et al. Frequent alterations in the Wnt signaling pathway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer. 2002;3:73–81.CrossRefGoogle Scholar
  31. 31.
    Leslie A, Carey F, Pratt N, et al. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002;89:845–860.PubMedCrossRefGoogle Scholar
  32. 32.
    Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature. 2000;408:307–310.PubMedCrossRefGoogle Scholar
  33. 33.
    Levine A. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331.PubMedCrossRefGoogle Scholar
  34. 34.
    Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9:724–737.PubMedCrossRefGoogle Scholar
  35. 35.
    Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat. 2003;21:176–181.PubMedCrossRefGoogle Scholar
  36. 36.
    Cho K, Oliner J, Simons J, et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics. 1994;19: 525–531.PubMedCrossRefGoogle Scholar
  37. 37.
    Takagi Y, Kohmura H, Futamura M, et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology. 1996;111:1369–1372.PubMedCrossRefGoogle Scholar
  38. 38.
    Takagi Y, Koumura H, Futamura M, et al. Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer. 1995;78:1152–1155.CrossRefGoogle Scholar
  39. 39.
    Wu C, Kirley S, Xiao H, et al. Cables enhances cdk2 tyrosine 152 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res. 2001;61:7325–7332.PubMedGoogle Scholar
  40. 40.
    Park do Y, Sakamoto H, Kirley S, et al. The Cables gene on chromosomes 18q is silences by promoter hypermethylation and allelic loss in human colorectal cancer. Am J Pathol. 2007;171:1509–1519.PubMedCrossRefGoogle Scholar
  41. 41.
    Chan TL, Zhao W, Leung SY, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003;63:4878–4881.PubMedGoogle Scholar
  42. 42.
    Samuels Y, Wang Z, Bardelli A, et al. High frequency if mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMedCrossRefGoogle Scholar
  43. 43.
    Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221–1224.PubMedCrossRefGoogle Scholar
  44. 44.
    Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001;293:1068–1070.PubMedCrossRefGoogle Scholar
  45. 45.
    Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation—A fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196.PubMedCrossRefGoogle Scholar
  47. 47.
    Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–167.PubMedCrossRefGoogle Scholar
  49. 49.
    Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808–811.PubMedGoogle Scholar
  50. 50.
    Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686–692.PubMedCrossRefGoogle Scholar
  51. 51.
    Ahuja N, Li Q, Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998;58:5489–5494.PubMedGoogle Scholar
  52. 52.
    Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536–540.PubMedCrossRefGoogle Scholar
  53. 53.
    Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31:141–149.PubMedCrossRefGoogle Scholar
  54. 54.
    Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24:132–138.PubMedCrossRefGoogle Scholar
  55. 55.
    Toyota M, Shen L, Ohe-Toyota M, et al. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000;60:4044–4048.PubMedGoogle Scholar
  56. 56.
    Devereux TR, Horikawa I, Anna CH, et al. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res. 1999;59:6087–6090.PubMedGoogle Scholar
  57. 57.
    Ahuja N, Mohan AL, Li Q, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res. 1997;57:3370–3374.PubMedGoogle Scholar
  58. 58.
    Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122:1376–1387.PubMedCrossRefGoogle Scholar
  59. 59.
    Whitehall VL, Wynter CV, Walsh MD, et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res. 2002;62:6011–6014.PubMedGoogle Scholar
  60. 60.
    Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer. 2004;108:237–242.PubMedCrossRefGoogle Scholar
  61. 61.
    Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003;63:5209–5212.PubMedGoogle Scholar
  62. 62.
    Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60:2368–2371.PubMedGoogle Scholar
  63. 63.
    Rashid A, Shen L, Morris JS, et al. CpG island methylation in colorectal adenomas. Am J Pathol. 2001;159:1129–1135.PubMedCrossRefGoogle Scholar
  64. 64.
    Chan AO, Broaddus RR, Houlihan PS, et al. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002;160:1823–1830.PubMedCrossRefGoogle Scholar
  65. 65.
    Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA. 2003;100:8412–8417.PubMedCrossRefGoogle Scholar
  66. 66.
    Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology. 1996;110:748–755.PubMedCrossRefGoogle Scholar
  67. 67.
    Rashid A, Houlihan PS, Booker S, et al. Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology. 2000;119:323–332.PubMedCrossRefGoogle Scholar
  68. 68.
    Jeevaratnam P, Cottier DS, Browett PJ, et al. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J Pathol. 1996;179:20–25.PubMedCrossRefGoogle Scholar
  69. 69.
    Park SJ, Rashid A, Lee JH, et al. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol. 2003;162:815–822.PubMedCrossRefGoogle Scholar
  70. 70.
    Chan AO, Issa JP, Morris JS, et al. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol. 2002;160:529–536.PubMedCrossRefGoogle Scholar
  71. 71.
    Jass JR. Serrated route to colorectal cancer: back street or super highway? J Pathol. 2001;193:283–285.PubMedCrossRefGoogle Scholar
  72. 72.
    Hawkins NJ, Bariol C, Ward RL. The serrated neoplasia pathway. Pathology. 2002;34:548–555.PubMedGoogle Scholar
  73. 73.
    Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst. 2001;93:1307–1313.PubMedCrossRefGoogle Scholar
  74. 74.
    Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994;368:258–261.PubMedCrossRefGoogle Scholar
  75. 75.
    Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263:1625–1629.PubMedCrossRefGoogle Scholar
  76. 76.
    Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutation of a Muts D homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75:1215–1225.PubMedCrossRefGoogle Scholar
  77. 77.
    Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027–1038 [Erratum, Cell 1994;77:167].PubMedCrossRefGoogle Scholar
  78. 78.
    Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet. 1997;17:271–272.PubMedCrossRefGoogle Scholar
  79. 79.
    Koldner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res. 1999;59:5068–5074.Google Scholar
  80. 80.
    Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371:75–80.PubMedCrossRefGoogle Scholar
  81. 81.
    Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95:6870–6875.PubMedCrossRefGoogle Scholar
  82. 82.
    Veigel ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing MSI cancers. Proc Natl Acad Sci USA. 1998;95:8698–8702.CrossRefGoogle Scholar
  83. 83.
    Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite instability for cancer detection and familial predisposition: development of international criteria for the detection of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5275.PubMedGoogle Scholar
  84. 84.
    Malkhosyan SR, Yamamoto H, Piao Z, et al. Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated hMLH1 gene in women. Gastroenterology. 2000; 119:598.PubMedCrossRefGoogle Scholar
  85. 85.
    Wright CM, Dent OF, Barker M, et al. The prognostic significance of extensive microsatellite instability in sporadic clinicopathologic stage C colorectal cancer. Br J Surg. 2000;87:1197–1202.PubMedCrossRefGoogle Scholar
  86. 86.
    Alexander J, Watanabe T, Wu TT, et al. Histopathologic identification of colon cancer with microsatellite instability. Am J Pathol. 2001;98:527–735.CrossRefGoogle Scholar
  87. 87.
    Kim H, Jen J, Vogelstein B, et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145:148–156.PubMedGoogle Scholar
  88. 88.
    Rüschoff J, Dietmaier W, Lüttges J, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150: 1815–1825.PubMedGoogle Scholar
  89. 89.
    Fujiwara T, Stolker JM, Watanabe T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol. 1998;153:1063–1078.PubMedCrossRefGoogle Scholar
  90. 90.
    Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alteration in colon cancer. Am J Pathol. 2001;158:1517–1524.PubMedCrossRefGoogle Scholar
  91. 91.
    Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 1999;59:3346–3351.PubMedGoogle Scholar
  92. 92.
    Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–195.PubMedCrossRefGoogle Scholar
  93. 93.
    Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336–1338.PubMedCrossRefGoogle Scholar
  94. 94.
    Souza RF, Appel R, Yin J, et al. The insulin-like growth factor II receptor gene is a target of microsatellite instability in human gastrointestinal tumors. Nat Genet. 1996;14:255–257.PubMedCrossRefGoogle Scholar
  95. 95.
    Yamamoto H, Sawai H, Weber TK, et al. Somatic frameshift mutations in hereditary nonpolyposis colorectal cancer. Cancer Res. 1998;58:997–1003.PubMedGoogle Scholar
  96. 96.
    Parsons R, Myeroff L, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995;55:5548–5550.PubMedGoogle Scholar
  97. 97.
    Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213–221.PubMedCrossRefGoogle Scholar
  98. 98.
    Watanabe T, Wu T-T, Catalano PJ, et al. Molecular predictors of survival after chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–1206.PubMedCrossRefGoogle Scholar
  99. 99.
    Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.PubMedCrossRefGoogle Scholar
  100. 100.
    Shen L, Catalano PJ, Benson AB III, et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 2007;13:6093–6098.PubMedCrossRefGoogle Scholar
  101. 101.
    Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129:837–845.PubMedCrossRefGoogle Scholar
  102. 102.
    Jover R, Nguyen T-P, Perez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival with CpG adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011;140:1174–1181.PubMedCrossRefGoogle Scholar
  103. 103.
    Rubic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–257.CrossRefGoogle Scholar
  104. 104.
    Liévre A, Bachet JB, Le Corre D, et al. KRAS mutation is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995.PubMedCrossRefGoogle Scholar
  105. 105.
    Liévre A, Bachet JB, Boige V, et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–379.PubMedCrossRefGoogle Scholar
  106. 106.
    Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008;68:1953–1961 [Erratum, Cancer Res 2008;68:6859.].PubMedCrossRefGoogle Scholar
  107. 107.
    Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924–5930.PubMedCrossRefGoogle Scholar
  108. 108.
    van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med. 2009;360:1408–1417.CrossRefGoogle Scholar
  109. 109.
    De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, AND PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–762.PubMedCrossRefGoogle Scholar
  110. 110.
    Warth A, Kloor M, Schirmacher P, et al. Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. Mod Pathol. 2011;24:564–570.PubMedCrossRefGoogle Scholar
  111. 111.
    Diosdado B, Buffart TE, Watkins R, et al. High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. Clin Cancer Res. 2010;16:1391–1401.PubMedCrossRefGoogle Scholar
  112. 112.
    Blaker H, von Herbay A, Penzel R, et al. Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene. Oncogene. 2002;21:158–164.PubMedCrossRefGoogle Scholar
  113. 113.
    Berkhout M, Nagtegaal ID, Cornelissen SJ, et al. Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas. Mod Pathol. 2007;20: 1253–1262.PubMedCrossRefGoogle Scholar
  114. 114.
    Rashid A, Hamilton SR. Genetic alterations in sporadic and Crohn’s-associated adenocarcinomas of the small intestine. Gastroenterology. 1997;113:127–135.PubMedCrossRefGoogle Scholar
  115. 115.
    Wheeler JM, Warren BF, Mortensen NJ, et al. An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut. 2002;50:218–223.PubMedCrossRefGoogle Scholar
  116. 116.
    Arai M, Shimizu S, Imai Y, et al. Mutations of the Ki-ras, p53 and APC genes in adenocarcinomas of the human small intestine. Int J Cancer. 1997;70:390–395.PubMedCrossRefGoogle Scholar
  117. 117.
    Zhang MQ, Chen ZM, Wang HL. Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol. 2006;19:573–580.PubMedCrossRefGoogle Scholar
  118. 118.
    Younes N, Fulton N, Tanaka R, et al. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer. 1997;79:1804–1808.PubMedCrossRefGoogle Scholar
  119. 119.
    Muneyuki T, Watanabe M, Yamanaka M, et al. Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas. Dig Dis Sci. 2000;45:2022–2028.PubMedCrossRefGoogle Scholar
  120. 120.
    Schonleben F, Qiu W, Allendorf JD, et al. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg. 2009;13:1510–1516.PubMedCrossRefGoogle Scholar
  121. 121.
    Kim SG, Chan AOO, Wu TT, et al. Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. Gastroenterology. 2003;124:1300–1310.PubMedCrossRefGoogle Scholar
  122. 122.
    Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterization of adenocarcinoma of the small intestine. Br J Cancer. 2010;102:144–150.PubMedCrossRefGoogle Scholar
  123. 123.
    Lynch HT, Lynch JF, Lynch PM, et al. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer. 2008;7:27–39.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of PathologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations